Hepatitis C infection is very rarely treated among hemodialysis patients

American Journal of Nephrology

Volumn 38, Issue 5, 2013, Pages 405-412

  Goodkin, David A ^a   Bieber, Brian ^a   Gillespie, Brenda ^b   Robinson, Bruce M ^a   Jadoul, Michel ^c  

^a ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Antiviral; Dialysis Outcomes and Practice Patterns Study; Hepatitis C; Interferon; Mortality; Ribavirin; Transplantation

Indexed keywords

HEPATITIS C ANTIBODY; PEGINTERFERON; RIBAVIRIN; ANTIVIRUS AGENT; INTERFERON;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HEMODIALYSIS PATIENT; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; CONTROLLED STUDY; MULTICENTER STUDY (TOPIC); PRESCRIPTION; PROPENSITY SCORE; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84886734901     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000355615     Document Type: Article

References (27)

1. Young EW, Goodkin DA, Mapes DL, Port FK, Keen ML, Chen K, Maroni BL, Wolfe RA, Held P: The Dialysis Outcomes and Practice Patterns Study: an international hemodialysis study. Kidney Int 2000; 57:S74-S81.
2. Pisoni RL, Gillespie BW, Dickinson DM, Chen K, Kutner MH, Wolfe RA: The Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data elements, and methodology. Am J Kidney Dis 2004; 44(suppl 2): 7-15.
3. Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, Rayner HC, Greenwood RN, Akiba T, Young EW: Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004; 65: 2335-2342. (Pubitemid 38670020)
4. Centers for Disease Control and Prevention: Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001; 50(RR-5):1-43.
5. Pereira BJG, Natov SN, Bouthot BA, Murthy BVR, Ruthazer R, Schmid CH, Levey AS, The New England Organ Bank Hepatitis C Study Group: Effect of hepatitis C infection and renal transplantation on survival in end-stage renal disease. Kidney Int 1998; 53: 1374-1381. (Pubitemid 28316901)
6. Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ: Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 1998; 32: 629-634. (Pubitemid 28477710)
7. Nakayama E, Akiba T, Marumo F, Sato C: Prognosis of anti-hepatitis C virus antibodypositive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000; 11: 1896-1902.
8. Espinosa M, Martin-Malo A, Alvarez de Lara MA, Aljama P: Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant 2001; 16: 1669-1674. (Pubitemid 32750462)
9. Johnson DW, Dent H, Yao Q, Tranaeus A, Huang C-C, Han D-S, Jha V, Wang T, Kawaguchi Y, Qian J: Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol Dial Transplant 2009; 24: 1598-1603.
10. Guh J-Y, Lai Y-H, Yang C-Y, Chen S-C, Chuang W-L, Hsu T-C, Chen H-C, Chang W-Y, Tsai J-H: Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. Nephron 1995; 69: 459-465.
11. Fabrizi F, Lunghi G, Finazzi S, Colucci P, Pagano A, Ponticelli C, Locatelli F: Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am J Kidney Dis 2001; 38: 1009-1015. (Pubitemid 33022178)
12. Contreras AM, Ruiz I, Polanco-Cruz G, Monteon FJ, Celis A, Vazquez G, Gomez-Herrera E, Garcia-Correa JE, Male-Velazquez R, Ruelas- Hernandez S: End-stage renal disease and hepatitis C infection: comparison of alanine aminotransferase levels and liver histology in patients with and without renal damage. Ann Hepatol 2007; 6: 48-54. (Pubitemid 46407489)
13. Morales JM, Campistol JM, Dominguez-Gil B, Andres A, Esforzado N, Oppenheimer F, Castellano G, Fuertes A, Bruquera M, Praga M: Long-term experience with kidney transplantation from hepatitis C-positive donors into hepatitis C-positive recipients. Am J Transplant 2010; 10: 2453-2462.
14. Kidney Disease: Improving Global Outcome: KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease. Kidney Int 2008; 73(suppl 109):S1-S99.
15. Liu C-H, Liang C-C, Lin J-W, Chen S-I, Tsai H-B, Chang C-S, Hung P-H, Kao J-H, Liu C-J, Lai M-Y, Chen J-H, Chen P-J, Kao J-H, Chen D-S: Pegylated interferon ?-2a versus standard interferon ?-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut 2008; 57: 525-530. (Pubitemid 351442538)
16. Berenguer M: Treatment of chronic hepatitis C in hemodialysis patients. Hepatology 2009; 48: 1690-1699.
17. Bruchfeld A, Stahle L, Andersson J, Schvarcz R: Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection - a pilot study. J Viral Hepat 2001; 8: 287-292. (Pubitemid 32673741)
18. Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT: Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. Int J Artif Organs 2008; 31: 295-302. (Pubitemid 351890659)
19. Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-1171.
20. Ghany MG, Strader DB, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
21. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB: Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis 2008; 51: 263-277.
22. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, McCredie M, Bovie P: Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 93-99. (Pubitemid 29313142)
23. Kalantar-Zadeh K, McAllister CJ, Miller LG: Clinical characteristics and mortality in hepatitis C-positive haemodialysis patients: a population based study. Nephrol Dial Transplant 2005; 20: 1662-1669. (Pubitemid 41418592)
24. Satayathum S, Pisoni RL, McCullough KP, Merion RM, Wikstrom B, Levin N, Chen K, Wolfe RA, Goodkin DA, Piera L, Asano Y, Kurokawa K, Fukuhara S, Held PJ, Port FK: Kidney transplantation and wait-listing rates from the international Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 2005; 68: 330-337. (Pubitemid 43181392)
25. Newstead CG, Davis CL: Evaluation and preoperative management of kidney transplant recipient and donor; in Feehally J, Floege J, Johnson RJ (eds): Comprehensive Clinical Nephrology, ed 3. Philadelphia, Mosby Elsevier, 2007, pp 1049-1059.
26. Weclawiak H, Kamar N, Ould-Mohamed A, Cardeau-Desangles I, Izopet J, Rostaing L: Treatment of chronic hepatitis C virus infection in dialysis patients: an update. Hepat Res Treat 2010; 2010: 267412.
27. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G: Hepatitis C virus antibody status and survival after renal transplantation: metaanalysis of observational studies. Am J Transplant 2005; 5: 1452-1461. (Pubitemid 40839438)